Effects of in-hospital rehabilitation on cardiovascular risk factors in patients with coronary heart disease;Auswirkung stationarer rehabilitation auf kardiovaskulare risikofaktoren bei patienten reit koronarer herzerkrankung

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 27, 1999, Pages 817-823

  Voller H ^a   Hahmann, H ^b   Gohlke, H ^c   Klein, G ^d   Rombeck, B ^a   Binting, S ^e   Willich, S N ^e  

^a Klinik Am See   (Germany)

^b Klinik Schwabenland   (Germany)

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^d Rehabilitationszentrum am Starnberger See   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; EVIDENCE BASED MEDICINE; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK MANAGEMENT; SECONDARY PREVENTION; AFTERCARE; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FOLLOW UP; GERMANY; HEART INFARCTION; HOSPITAL ADMISSION; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PROSPECTIVE STUDY; REHABILITATION CENTER; RISK FACTOR;

AFTERCARE; AGED; COHORT STUDIES; COMBINED MODALITY THERAPY; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT ADMISSION; PATIENT CARE TEAM; PROSPECTIVE STUDIES; REHABILITATION CENTERS; RISK FACTORS;

EID: 0033538395     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024425     Document Type: Article

References (41)

1. Avanzini, F., G. Zuaneti, R. Latini, F. Colombo, E. Santoro, A. P. Maggioni, M. G. Franzosi, G. Tognoni: Use of beta-blocking agents in secondary prevention after myocardial infarction. A case for evidence-based medicine? Europ. Heart J. 18 (1997), 1447-1456.
2. Bestehorn, H.-P., U. F. E. Rensing, H. Roskamm, P. Betz, L. Benesch, K. Schemeitat, G. Blümchen, J. Claus, P. Mathes, L. Kappenberger, H. Wieland, A. Neiss: The effect of simvastatin on progression of coronary artery disease. The Multicenter Coronary Intervention Study (CIS). Europ. Heart J. 18 (1997), 226-234.
3. Bjorck, S., G. Nyberg, H. Mulec, G. Granerus, H. Herlitz, M. Aurell: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Brit. Med. J. 293 (1986), 471-474.
4. Chambless, L., U. Keil, A. Dobson, M. Mähönen, K. Kuulasmaa, A.-M. Rajakangas, H. Löwel, H. Tunstall-Pedoe: Population versus clinical view of case fatality from acute coronary heart disease. Results from the WHO MONICA project 1985-1990. Circulation 96 (1997), 3849-3859.
5. Danias, P. G., S. O'Mahony, M. J. Radford, L. Korman, D. I. Silverman: Serum cholesterol levels are undervaluated and undertreated. Amer. J. Cardiol. 81 (1998), 1353-1356.
6. De Lorgeril, M., P. Salen, J.-L. Martin, N. Mamelle, I. Monjaud, P. Touboul, J. Delaye: Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. J. Amer. Coll. Cardiol. 28 (1996), 1103-1108.
7. Engbergs, A., A. Liese, M. Heimbach, S. Kerber, H. H. Scheld, G. Breithardt, P. Kleine-Kalthöfer, U. Keil: Sekundärprävention der koronaren herzkrankheit auf dem prüfstand. Z. Kardiol. 86 (1997), 284-291.
8. Estacio, R. O., B. W. Jeffers, W. R. Hiatt, S. L. Biggerstaff, N. Gifford, R. W. Schrier: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New Engl. J. Med. 338 (1998), 645-652.
9. EUROASPIRE study group: A european society of cardiology survey of secondary prevention of coronary heart disease. Principal results. Europ. Heart J. 18 (1997), 1569-1582.
10. Furberg, C. D., B. M. Psaty, J. V. Meyer: Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92(1995), 1331-1336.
11. Gheorghiade, M., B. Pitt: Digitalis investigation group (DIG) trial. A stimulus for further research. Amer. Heart J. 134 (1997), 3-12.
12. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinurie non-diabetic nephropathy. Lancet 349 (1997), 1857-1863.
13. Gottlieb, S. S., R. J. McCarter, R. A. Vogel: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. New Engl. J. Med. 339 (1998), 489-497.
14. Grande, G., T. Schott, B. Badura: Ergebnisorientierte Evaluation kardiologischer rehabilitation. Z. f. Gesundheits. Wiss. 4 (1996), 335-348.
15. Hasdai, D., K. N. Garratt, D. E. Grill, A. Lerman, D. R. Holmes: Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. New Engl. J. Med. 336 (1997), 755-761.
16. Haskell, W. L., E. L. Alderman, J.M. Fair, D. J. Maron, S. F. Mackey, R. Superko, P. T. Williams, I. M. Johnstone, M. A. Champagne, R. M. Krauss, J. W. Farquhar: Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 89 (1994), 975-990.
17. Hennekens, C. H., C. M. Albert, S. L. Godfried, J. M. Gaziano, J. E. Buring: Adjunctive drug therapy of acute myocardial infarction. Evidence from clinical trials. New Engl. J. Med. 335 (1996), 1660-1667.
18. Herd, J. A., C. M. Ballantyne, J. A. Farmer, J. J. Ferguson, P. H. Jones, S. West, K. L. Gould, A. M. Gotto: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Amer. J. Cardiol. 80 (1997), 278-286.
19. Ishikawa, K., S. Nakai, T. Takenaka, K. Kanamasa, J. Hama, I. Ogawa, T. Yamamoto, M. Oyaizu, A. Kimura, K. Yamamoto, H. Yabushita, R. Katori: Short acting nifedipine and diltiazem do not reduce the indicende of cardiac events in patients with healed myocardial infarction. Circulation 95 (1997), 2368-2373.
20. Julian, D. G.: An integrated approach to the management of patients after the acute phase of myocardial infarction. In Yusuf, S., J. A. Cairus, A. J. Camm, E. L. Falten, B. J. Gersh (Eds.): Evidence Based Cardiology. (BMJ Books: London 1998), 512-523.
21. Kendall, M. J., K. P. Lynch, A. Hjalmarson, J. Kjekshus: β-Blockers and sudden cardiac death. Ann. Intern. Med. 123 (1995), 358-367.
22. Lavie, C. J., R. V. Milani: Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients. Amer. J. Cardiol. 79 (1997), 397-401.
23. Leitch, J. W., P. McEldruff, A. Dobson, R. Heller: Outcome with calcium channel antagonists after myocardial infarction. A community-based study. J. Amer. Coll. Cardiol. 31 (1998), 111-117.
24. O'Driscoll, G., D. Green, R. R. Taylor: Simvastatin, an HMG-Coenzyme. A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997), 1126-1131.
25. Ommen, S. R., J. A. Odell, M. S. Stanton: Atrial arrhythmias after cardiothoracic surgery. New Engl. J. Med. 337 (1997), 1429-1434.
26. Ornish, D., S. E. Brown, L. W. Scherwitz, J. H. Billings, W. T. Armstrong, T. A. Ports, S. M. McLanahan, R. L. Kirkeeide, R. Brand, K. I. Gould: Can lifestyle changes reverse coronary heart disease? Lancet 336 (1990), 129-133.
27. Paffenberger, F. S., R. T. Hyde, A. L. Wing, I.-M. Lee, D. L. Jung, J. B. Kampert: The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. New Engl. J. Med. 328 (1993), 538-545.
28. Pedersen, T. R., A. G. Olsson, O. Færgeman, J. Kjekhus, H. Wedel, K. Berg, L. Wilhelmsen, R. Hafhfelt, G. Thorgeirsson, K. Pyörälä, T. Miettinen, C. Christophersen, J. A. Tobert, T. A. Musliner, T. J. Cook: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97 (1998), 1453-1460.
29. Pyörälä, K., G. de Backer, I. Graham, P. Poole-Wilson, D. Wood: Prevention of coronary heart disease in clinical practice. Europ. Heart J. 15(1994), 1300-1331.
30. Sacks, F., M., L. A. Moyé, B. R. Davis, T. G. Cole, J. L. Rouleau, D. T. Nash, M. A. Pfeffer, E. Braunwald: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 97 (1998), 1446-1452.
31. Sacks, F. M., M. A. Pfeffer, L. A. Moyé, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, W. Warnica, J. M. O. Arnold, C.-C. Wun, B. R. Davis, E. Braunwald: The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335 (1996), 1001-1009.
32. Schuster, S., A. Koch, U. Burczyk, R. Schiele, S. Wagner, R. Zahn, H. G. Glunz, F. Heinrich, K. Stuby, G. Berg, T. Voigtländer, U. Gieseler, M. Jakob, P. Hauptmann, J. Senges: Frühbehandlung des akuten myokardinfarktes. Umsetzung von therapierichtlinien in den klinischen alltag, MITRA-Pilotphase, Z. Kardiol. 86 (1997), 273-283.
33. Statistisches Bundesamt Deutschland: Todesursachen im Jahre 1996, http://www.statistik-bund.de/basis/d/gesulab3-htm
34. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl. J. Med. 336 (1997), 525-533.
35. The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range on initial cholesterol levels. New Engl. J. Med, 339 (1998), 1349-1357.
36. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383-1389.
37. Treasure, C. B., J. L. Klein, W. S. Weintraub, J. D. Talley, M. E. Stillabower, A. S. Konsinski, J. Zhang, S. J. Boccuzzi, C. Cedarholm, R. W. Alexander: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. New Engl. J. 332 (1995), 481-487.
38. Verdecchia, P., G. Schillaci, C. Borgioni, A: Ciucci, R. Gattobigio, I. Zampi, G. Reboldi, C. Procellati: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97 (1998), 48-54.
39. Wilson, P. W. F., J. M. Hoeg, R. B. D'Agostino, H. Silberschatz, A. M. Belanger, H. Poehlmann, D. O'Leary, P. A. Wolff: Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. New Engl. J. Med. 337 (1997), 516-522.
40. Woods, K. L., D. Ketley, A. Lowy, A. Agusti, C. Hagn, R. Kala, N. B. Karatzas, A. Leizorowicz, A. Reikvam, J. Schilling, R. Seabra-Gomes, D. Vasiliauskas, L. Wilhelmsen: Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Europ. Heart J. 19 (1998), 74-79.
41. Yusuf, S.: Digoxin in heart failure. Results of the recent digoxin investigation group trial in the context of other treatments for heart failure. Europ. Heart J. 18 (1997), 1685-1688.